RBC Capital downgraded Cidara Therapeutics (CDTX) to Sector Perform from Outperform with a price target of $221.50, up from $145, after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX: